Silencing of this gene leads to reduction of the p53 protein, contributing in boosting the aggressiveness of the tumor and its refractoriness to therapies; therefore, knowledge of its mutational status is crucial for the clinical management of CMM. This evidence concerns the gene TP53 and neoplasm.